{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:50:52Z","timestamp":1793375452953,"version":"4.5.0"},"reference-count":200,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Ministry of Health of the Russian Federation","award":["124020200111-6"],"award-info":[{"award-number":["124020200111-6"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Systemic inflammation and coronary microvascular endothelial dysfunction are essential pathophysiological factors in heart failure (HF) with preserved ejection fraction (HFpEF) that support the use of statins. The pleiotropic properties of statins, such as anti-inflammatory, antihypertrophic, antifibrotic, and antioxidant effects, are generally accepted and may be beneficial in HF, especially in HFpEF. Numerous observational clinical trials have consistently shown a beneficial prognostic effect of statins in patients with HFpEF, while the results of two larger trials in patients with HFrEF have been controversial. Such differences may be related to a more pronounced impact of the pleiotropic properties of statins on the pathophysiology of HFpEF and pro-inflammatory comorbidities (arterial hypertension, diabetes mellitus, obesity, chronic kidney disease) that are more common in HFpEF. This review discusses the potential mechanisms of statin action that may be beneficial for patients with HFpEF, as well as clinical trials that have evaluated the statin effects on left ventricular diastolic function and clinical outcomes in patients with HFpEF.<\/jats:p>","DOI":"10.3390\/ijms25094958","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T10:33:31Z","timestamp":1714559611000},"page":"4958","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Use of Statins in Heart Failure with Preserved Ejection Fraction: Current Evidence and Perspectives"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3285-6148","authenticated-orcid":false,"given":"Artem","family":"Ovchinnikov","sequence":"first","affiliation":[{"name":"Laboratory of Myocardial Fibrosis and Heart Failure with Preserved Ejection Fraction, National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Academician Chazov St., 15a, 121552 Moscow, Russia"},{"name":"Department of Clinical Functional Diagnostics, A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Delegatskaya St., 20, p. 1, 127473 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9290-9884","authenticated-orcid":false,"given":"Alexandra","family":"Potekhina","sequence":"additional","affiliation":[{"name":"Laboratory of Myocardial Fibrosis and Heart Failure with Preserved Ejection Fraction, National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Academician Chazov St., 15a, 121552 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9500-1940","authenticated-orcid":false,"given":"Tatiana","family":"Arefieva","sequence":"additional","affiliation":[{"name":"Laboratory of Cell Immunology, National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Academician Chazov St., 15a, 121552 Moscow, Russia"},{"name":"Faculty of Basic Medicine, Lomonosov Moscow State University, Leninskie Gory, 1, 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8911-1628","authenticated-orcid":false,"given":"Anastasiia","family":"Filatova","sequence":"additional","affiliation":[{"name":"Laboratory of Myocardial Fibrosis and Heart Failure with Preserved Ejection Fraction, National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Academician Chazov St., 15a, 121552 Moscow, Russia"},{"name":"Laboratory of Cell Immunology, National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Academician Chazov St., 15a, 121552 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fail","family":"Ageev","sequence":"additional","affiliation":[{"name":"Out-Patient Department, National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Academician Chazov St., 15a, 121552 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9940-0829","authenticated-orcid":false,"given":"Evgeny","family":"Belyavskiy","sequence":"additional","affiliation":[{"name":"Medizinisches Versorgungszentrum des Deutsches Herzzentrum der Charite, Augustenburger Platz 1, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcmg.2017.08.007","article-title":"Epidemiology of Left Ventricular Systolic Dysfunction and Heart Failure in the Framingham Study: An Echocardiographic Study Over 3 Decades","volume":"11","author":"Vasan","year":"2018","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/cvr\/cvy145","article-title":"Immunomodulatory interventions in myocardial infarction and heart failure: A systematic review of clinical trials and meta-analysis of IL-1 inhibition","volume":"114","author":"Panahi","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Simmonds, S.J., Cuijpers, I., Heymans, S., and Jones, E.A.V. (2020). Cellular and Molecular Differences between HFpEF and HFrEF: A Step Ahead in an Improved Pathological Understanding. Cells, 9.","DOI":"10.3390\/cells9010242"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","article-title":"Epidemiology of heart failure with preserved ejection fraction","volume":"14","author":"Dunlay","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jchf.2015.10.007","article-title":"Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction","volume":"4","author":"Franssen","year":"2016","journal-title":"JACC Heart Fail."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1161\/CIRCHEARTFAILURE.109.931451","article-title":"Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction","volume":"4","author":"Westermann","year":"2011","journal-title":"Circ. Heart Fail."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1161\/CIRCULATIONAHA.111.076075","article-title":"Low myocardial protein kinase G activity in heart failure with preserved ejection fraction","volume":"126","author":"Hamdani","year":"2012","journal-title":"Circulation."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic Effects of Statins on the Cardiovascular System","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1161\/01.CIR.101.2.207","article-title":"Current perspectives on statins","volume":"101","author":"Maron","year":"2000","journal-title":"Circulation."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration, Baigent, C., Blackwell, L., Emberson, J., Holland, L.E., Reith, C., Bhala, N., Peto, R., Barnes, E.H., and Keech, A. (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 376, 1670\u20131681.","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.amjcard.2018.04.027","article-title":"Comparison of Effects of Statin Use on Mortality in Patients With Heart Failure and Preserved Versus Reduced Left Ventricular Ejection Fraction","volume":"122","author":"Lee","year":"2018","journal-title":"Am. J. Cardiol."},{"key":"ref_14","first-page":"175","article-title":"Anti-inflammatory Action of Statins in Cardiovascular Disease: The Role of Inflammasome and Toll-Like Receptor Pathways. Clin. Rev","volume":"60","author":"Koushki","year":"2021","journal-title":"Allergy Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1161\/CIRCULATIONAHA.110.985150","article-title":"Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling","volume":"124","author":"Antoniades","year":"2011","journal-title":"Circulation."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jacc.2005.06.088","article-title":"Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure","volume":"47","author":"Sola","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.arcmed.2010.08.009","article-title":"Effects of statin therapy on inflammatory markers in chronic heart failure: A meta-analysis of randomized controlled trials","volume":"41","author":"Zhang","year":"2010","journal-title":"Arch. Med. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1097\/HJH.0000000000000184","article-title":"Atorvastatin ameliorates cardiac fibrosis and improves left ventricular diastolic function in hypertensive diastolic heart failure model rats","volume":"32","author":"Akahori","year":"2014","journal-title":"J. Hypertens."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/eurjhf\/hfq101","article-title":"Rosuvastatin added to standard heart failure therapy improves cardiac remodelling in heart failure rats with preserved ejection fraction","volume":"12","author":"Aragoncillo","year":"2010","journal-title":"Eur. J. Heart Fail."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1134\/S0006297918080023","article-title":"Immunotropic Effects and Proposed Mechanism of Action for 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Inhibitors (Statins)","volume":"83","author":"Arefieva","year":"2018","journal-title":"Biochemistry (Mosc.)"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s11427-015-4836-1","article-title":"Protein prenylation and human diseases: A balance of protein farnesylation and geranylgeranylation","volume":"58","author":"Xu","year":"2015","journal-title":"Sci. China Life Sci."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Soh, J.E.C., Shimizu, A., Sato, A., and Ogita, H. (2023). Novel cardiovascular protective effects of RhoA signaling and its therapeutic implications. Biochem. Pharmacol., 218.","DOI":"10.1016\/j.bcp.2023.115899"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Seccia, T.M., Rigato, M., Ravarotto, V., and Cal\u00f2, L.A. (2020). ROCK (RhoA\/Rho Kinase) in Cardiovascular-Renal Pathophysiology: A Review of New Advancements. J. Clin. Med., 9.","DOI":"10.3390\/jcm9051328"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jacc.2006.12.043","article-title":"Increased Rho kinase activity in a Taiwanese population with metabolic syndrome","volume":"49","author":"Liu","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/HJH.0b013e328340902d","article-title":"Calcium channel blocker and Rho-associated kinase activity in patients with hypertension","volume":"29","author":"Hata","year":"2011","journal-title":"J. Hypertens."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1161\/01.RES.0000251668.39526.c7","article-title":"Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease","volume":"99","author":"Nohria","year":"2006","journal-title":"Circ. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1158\/0008-5472.CAN-07-5807","article-title":"Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1\/2","volume":"68","author":"Lin","year":"2008","journal-title":"Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41586-019-1100-z","article-title":"Nitrosative stress drives heart failure with preserved ejection fraction","volume":"568","author":"Schiattarella","year":"2019","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s12551-015-0175-5","article-title":"A change of heart: Oxidative stress in governing muscle function?","volume":"7","author":"Breitkreuz","year":"2015","journal-title":"Biophys. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Gorabi, A.M., Kiaie, N., Hajighasemi, S., Banach, M., Penson, P.E., Jamialahmadi, T., and Sahebkar, A. (2019). Statin-Induced Nitric Oxide Signaling: Mechanisms and Therapeutic Implications. J. Clin. Med., 8.","DOI":"10.3390\/jcm8122051"},{"key":"ref_31","first-page":"3147","article-title":"Inhibition of Rho-kinase is involved in the therapeutic effects of atorvastatin in heart ischemia\/reperfusion","volume":"20","author":"Cheng","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1161\/01.RES.83.3.334","article-title":"Fluid shear stress stimulates phosphorylation of Akt in human endothelial cells: Involvement in suppression of apoptosis","volume":"83","author":"Dimmeler","year":"1998","journal-title":"Circ. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.108.813311","article-title":"Evidence for statin pleiotropy in humans: Differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation","volume":"119","author":"Liu","year":"2009","journal-title":"Circulation."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.amjcard.2008.10.008","article-title":"Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event","volume":"103","author":"Rawlings","year":"2009","journal-title":"Am. J. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1089\/ars.2013.5430","article-title":"Statins as regulators of redox state in the vascular endothelium: Beyond lipid lowering","volume":"20","author":"Margaritis","year":"2014","journal-title":"Antioxid. Redox Signal."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1161\/01.CIR.0000065601.83526.3E","article-title":"Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-\/- mice in vivo","volume":"107","author":"Pelat","year":"2003","journal-title":"Circulation"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.lfs.2010.05.008","article-title":"Effect of simvastatin on Kruppel-like factor2, endothelial nitric oxide synthase and thrombomodulin expression in endothelial cells under shear stress","volume":"87","author":"Rossi","year":"2010","journal-title":"Life Sci."},{"key":"ref_38","first-page":"130","article-title":"Long-term pleiotropic effect of statins upon nitric oxide and C-reactive protein levels in patients with peripheral arterial disease","volume":"3","author":"Bleda","year":"2011","journal-title":"Heart Asia"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1161\/hc2401.092816","article-title":"Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease","volume":"103","author":"Vasa","year":"2001","journal-title":"Circulation"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cardiores.2005.02.008","article-title":"Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts","volume":"66","author":"Taccardi","year":"2005","journal-title":"Cardiovasc. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1023\/A:1022103222857","article-title":"Statins and the role of nitric oxide in chronic heart failure","volume":"8","author":"Anker","year":"2003","journal-title":"Heart Fail. Rev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00441-014-1809-9","article-title":"Leukocyte recruitment in inflammation: Basic concepts and new mechanistic insights based on new models and microscopic imaging technologies","volume":"355","author":"Leick","year":"2014","journal-title":"Cell Tissue Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s10741-013-9405-8","article-title":"Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target","volume":"19","author":"Glezeva","year":"2014","journal-title":"Heart Fail. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1084\/jem.20171274","article-title":"Cardiac macrophages promote diastolic dysfunction","volume":"215","author":"Hulsmans","year":"2018","journal-title":"J. Exp. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"H1287","DOI":"10.1152\/ajpheart.00096.2016","article-title":"Cardiac-deleterious role of galectin-3 in chronic angiotensin II-induced hypertension","volume":"311","author":"Rhaleb","year":"2016","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_46","first-page":"II18","article-title":"Inflammation, immunity, and HMG-CoA reductase inhibitors: Statins as antiinflammatory agents?","volume":"109","author":"Libby","year":"2004","journal-title":"Circulation."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pcad.2021.02.008","article-title":"Effects of statins on myocarditis: A review of underlying molecular mechanisms","volume":"67","author":"Parsamanesh","year":"2021","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"592576","DOI":"10.1155\/2013\/592576","article-title":"Cholesterol Contributes to Diabetic Nephropathy through SCAP-SREBP-2 Pathway","volume":"2013","author":"Sun","year":"2013","journal-title":"Int. J. Endocrinol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.expneurol.2009.09.013","article-title":"Cholesterol and statins in Alzheimer\u2019s disease: Current controversies","volume":"223","author":"Fonseca","year":"2010","journal-title":"Exp. Neurol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e13534","DOI":"10.1111\/eci.13534","article-title":"The role of statins in the differentiation and function of bone cells","volume":"51","author":"Chamani","year":"2021","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2741\/3702","article-title":"Functional role of Akt in macrophage-mediated innate immunity","volume":"16","author":"Lee","year":"2011","journal-title":"Front. Biosci. (Landmark Ed.)"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"40","DOI":"10.32607\/actanaturae.11154","article-title":"The Molecular and Cellular Mechanisms Associated with a Microvascular Inflammation in the Pathogenesis of Heart Failure with Preserved Ejection Fraction","volume":"12","author":"Ovchinnikov","year":"2020","journal-title":"Acta Nat."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/labinvest.3780115","article-title":"Inhibition of monocyte chemotactic protein-1 synthesis by statins","volume":"80","author":"Romano","year":"2000","journal-title":"Lab. Investig."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/89058","article-title":"Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site","volume":"7","author":"Welzenbach","year":"2001","journal-title":"Nat. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.atherosclerosis.2005.10.015","article-title":"Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages","volume":"188","author":"Veillard","year":"2006","journal-title":"Atherosclerosis"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1995-7645(13)60081-4","article-title":"Effect of atorvastatin on expression of TLR4 and NF-\u03baB p65 in atherosclerotic rabbits","volume":"6","author":"Shen","year":"2013","journal-title":"Asian Pac. J. Trop. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0014-2999(98)00692-X","article-title":"Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes","volume":"361","author":"Yamamoto","year":"1998","journal-title":"Eur. J. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0021-9150(01)00547-0","article-title":"Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells","volume":"160","author":"Ortego","year":"2002","journal-title":"Atherosclerosis"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"15099","DOI":"10.1074\/jbc.M600200200","article-title":"Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-\u03baB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin","volume":"281","author":"Chandrasekar","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/08860220902835863","article-title":"Atorvastatin prevents gentamicin-induced renal damage in rats through the inhibition of p38-MAPK and NF-\u03baB pathways","volume":"31","author":"Ozbek","year":"2009","journal-title":"Ren. Fail."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3390\/immuno2020021","article-title":"The Immunomodulatory Effects of Statins on Macrophages","volume":"2","author":"Sheridan","year":"2022","journal-title":"Immuno"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"879021","DOI":"10.3389\/fnagi.2022.879021","article-title":"The NLRP3 Inflammasome Pathway: A Review of Mechanisms and Inhibitors for the Treatment of Inflammatory Diseases","volume":"14","author":"Blevins","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Lim, K.H., and Staudt, L.M. (2013). Toll-like receptor signaling. Cold Spring Harb. Perspect. Biol., 5.","DOI":"10.1101\/cshperspect.a011247"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1124\/mol.116.108100","article-title":"Statins Attenuate Activation of the NLRP3 Inflammasome by Oxidized LDL or TNF\u03b1 in Vascular Endothelial Cells through a PXR-Dependent Mechanism","volume":"92","author":"Wang","year":"2017","journal-title":"Mol. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.phrs.2018.08.014","article-title":"Effect of statins on toll-like receptors: A new insight to pleiotropic effects","volume":"135","author":"Bahrami","year":"2018","journal-title":"Pharmacol. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.atherosclerosis.2012.08.037","article-title":"Effect of simvastatin or its combination with ezetimibe on Toll-like receptor expression and lipopolysaccharide-induced cytokine production in monocytes of hypercholesterolemic patients","volume":"225","author":"Moutzouri","year":"2012","journal-title":"Atherosclerosis"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1161\/01.ATV.0000043456.48735.20","article-title":"HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells","volume":"23","author":"Dichtl","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/07853890.2016.1197413","article-title":"Clinical relevance for lowering C-reactive protein with statins","volume":"48","year":"2016","journal-title":"Ann. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1161\/01.CIR.0000096055.62724.C5","article-title":"Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells","volume":"108","author":"Willerson","year":"2003","journal-title":"Circulation"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"DuBrock, H.M., AbouEzzeddine, O.F., and Redfield, M.M. (2018). High-sensitivity C-reactive protein in heart failure with preserved ejection fraction. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0201836"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s10741-020-09927-x","article-title":"Diagnostic and prognostic value of serum C-reactive protein in heart failure with preserved ejection fraction: A systematic review and meta-analysis","volume":"26","author":"Lakhani","year":"2021","journal-title":"Heart Fail. Rev."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1161\/CIRCULATIONAHA.113.004243","article-title":"C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy","volume":"128","author":"Puri","year":"2013","journal-title":"Circulation"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1016\/j.jacc.2014.08.045","article-title":"Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: The EASY-FIT study","volume":"64","author":"Komukai","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jacc.2015.05.056","article-title":"Effect of Intensive Statin Therapy on Coronary High-Intensity Plaques Detected by Noncontrast T1-Weighted Imaging: The AQUAMARINE Pilot Study","volume":"66","author":"Noguchi","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/1755-5922.12150","article-title":"Effects of Statin Treatment on Inflammation and Cardiac Function in Heart Failure: An Adjusted Indirect Comparison Meta-Analysis of Randomized Trials","volume":"33","author":"Bonsu","year":"2015","journal-title":"Cardiovasc. Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/rheumatology\/ken466","article-title":"Statins inhibit C-reactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes","volume":"48","author":"Montecucco","year":"2009","journal-title":"Rheumatology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1064967","DOI":"10.3389\/fcvm.2022.1064967","article-title":"C-reactive protein and statins in heart failure with reduced and preserved ejection fraction","volume":"9","author":"Park","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12935-023-02890-1","article-title":"Paradoxical effects of statins on endothelial and cancer cells: The impact of concentrations","volume":"23","author":"Ahmadi","year":"2023","journal-title":"Cancer Cell Int."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Walkowski, B., Kleibert, M., Majka, M., and Wojciechowska, M. (2022). Insight into the Role of the PI3K\/Akt Pathway in Ischemic Injury and Post-Infarct Left Ventricular Remodeling in Normal and Diabetic Heart. Cells, 11.","DOI":"10.3390\/cells11091553"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1002\/eji.200838189","article-title":"The IFN-\u03b3-Induced Transcriptional Program of the CIITA Gene Is Inhibited by Statins","volume":"38","author":"Lee","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Leuenberger, T., Pfueller, C.F., Luessi, F., Bendix, I., Paterka, M., Prozorovski, T., Treue, D., Luenstedt, S., Herz, J., and Siffrin, V. (2014). Modulation of dendritic cell immunobiology via inhibition of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0100871"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e003976","DOI":"10.1161\/JAHA.116.003976","article-title":"Oxidized Low-Density Lipoprotein (OxLDL)-Treated Dendritic Cells Promote Activation of T Cells in Human Atherosclerotic Plaque and Blood, Which Is Repressed by Statins: MicroRNA let-7c Is Integral to the Effect","volume":"5","author":"Zhang","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10517-021-05350-w","article-title":"Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (statins) suppress human CD4+ T lymphocytes proliferation and motility in vitro","volume":"172","author":"Radyukhina","year":"2021","journal-title":"Bull. Exp. Biol. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10517-020-05042-x","article-title":"Inhibitors of 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase (Statins) Suppress Differentiation and Reduce LPS IFN\u03b3-Induced Cytokine Production in Human Monocyte Macrophage Culture","volume":"170","author":"Ruleva","year":"2020","journal-title":"Bull. Exp. Biol. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1002\/eji.200636567","article-title":"Simvastatin inhibits the MHC class II pathway of antigen presentation by impairing Ras superfamily GTPases","volume":"36","author":"Ghittoni","year":"2006","journal-title":"Eur. J. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0165-6147(02)02077-1","article-title":"Statins as anti-inflammatory agents","volume":"23","year":"2002","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"46","DOI":"10.14336\/AD.2022.0523","article-title":"The NO-cGMP-PKG Axis in HFpEF: From Pathological Mechanisms to Potential Therapies","volume":"14","author":"Cai","year":"2023","journal-title":"Aging Dis."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Lugnier, C., Meyer, A., Charloux, A., Andr\u00e8s, E., G\u00e9ny, B., and Talha, S. (2019). The Endocrine Function of the Heart: Physiology and Involvements of Natriuretic Peptides and Cyclic Nucleotide Phosphodiesterases in Heart Failure. J. Clin. Med., 8.","DOI":"10.3390\/jcm8101746"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"153633","DOI":"10.1016\/j.phymed.2021.153633","article-title":"An herbal preparation ameliorates heart failure with preserved ejection fraction by alleviating microvascular endothelial inflammation and activating NO-cGMP-PKG pathway","volume":"91","author":"Huang","year":"2021","journal-title":"Phytomedicine"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12933-019-0914-1","article-title":"Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction","volume":"18","author":"Zhang","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/cvr\/cvaa123","article-title":"Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase G\u03b1 oxidation","volume":"117","author":"Kolijn","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_92","first-page":"408","article-title":"Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice","volume":"119","author":"Takimoto","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1161\/CIRCRESAHA.114.302614","article-title":"Hyperactive adverse mechanical stress responses in dystrophic heart are coupled to transient receptor potential canonical 6 and blocked by cGMP-protein kinase G modulation","volume":"114","author":"Seo","year":"2014","journal-title":"Circ. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00395-018-0690-1","article-title":"A concise discussion of the regulatory role of cGMP kinase I in cardiac physiology and pathology","volume":"113","author":"Hofmann","year":"2018","journal-title":"Basic Res. Cardiol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"102207","DOI":"10.1016\/j.coph.2022.102207","article-title":"Smad-dependent pathways in the infarcted and failing heart","volume":"64","author":"Humeres","year":"2022","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1161\/CIRCRESAHA.107.170217","article-title":"Cyclic GMP\/protein kinase G phosphorylation of Smad3 blocks transforming growth factor-beta-induced nuclear Smad translocation: A key antifibrogenic mechanism of atrial natriuretic peptide","volume":"102","author":"Buxton","year":"2008","journal-title":"Circ. Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/FJC.0000000000000007","article-title":"Cardiac titin and heart disease","volume":"63","author":"LeWinter","year":"2014","journal-title":"J. Cardiovasc. Pharm."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/cvr\/cvs353","article-title":"Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction","volume":"97","author":"Hamdani","year":"2013","journal-title":"Cardiovasc. Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1161\/CIRCULATIONAHA.114.013215","article-title":"Myocardial stiffness in patients with heart failure and a preserved ejection fraction: Contributions of collagen and titin","volume":"131","author":"Zile","year":"2015","journal-title":"Circulation"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.rmed.2016.08.022","article-title":"Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence","volume":"122","author":"Sandner","year":"2017","journal-title":"Resp. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e96006","DOI":"10.1172\/jci.insight.96006","article-title":"Nitric oxide-sensitive guanylyl cyclase stimulation improves experimental heart failure with preserved ejection fraction","volume":"3","author":"Wilck","year":"2018","journal-title":"JCI Insight."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e005565","DOI":"10.1161\/CIRCHEARTFAILURE.118.005565","article-title":"Sacubitril\/Valsartan Decreases Cardiac Fibrosis in Left Ventricle Pressure Overload by Restoring PKG Signaling in Cardiac Fibroblasts","volume":"12","author":"Burke","year":"2019","journal-title":"Circ. Heart Fail."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"792798","DOI":"10.3389\/fphar.2022.792798","article-title":"Cyclic GMP and PKG Signaling in Heart Failure","volume":"13","author":"Numata","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jacc.2007.10.009","article-title":"Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy","volume":"51","author":"Ramasubbu","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jacc.2011.08.062","article-title":"Myocardial redox state predicts in-hospital clinical outcome after cardiac surgery effects of short-term pre-operative statin treatment","volume":"59","author":"Antoniades","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jchf.2020.04.007","article-title":"Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis","volume":"8","author":"Hahn","year":"2020","journal-title":"JACC Heart Fail."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJM199210013271406","article-title":"The heart in hypertension","volume":"327","author":"Frohlich","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1161\/01.CIR.0000127939.16111.58","article-title":"Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice","volume":"109","author":"Hattori","year":"2004","journal-title":"Circulation"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0008-6363(02)00457-1","article-title":"Critical role of Rho-kinase pathway for cardiac performance and remodeling in failing rat hearts","volume":"55","author":"Kobayashi","year":"2002","journal-title":"Cardiovasc. Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/00005344-200212000-00007","article-title":"Association of pravastatin and left ventricular mass in hypercholesterolemic patients: Role of 8-iso-prostaglandin f2alpha formation","volume":"40","author":"Lee","year":"2002","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.1073\/pnas.0510444103","article-title":"Requirement of Rac1 in the development of cardiac hypertrophy","volume":"103","author":"Satoh","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1161\/ATVBAHA.112.300922","article-title":"Statins exert the pleiotropic effects through small GTP-binding protein dissociation stimulator upregulation with a resultant Rac1 degradation","volume":"33","author":"Tanaka","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1161\/HYPERTENSIONAHA.115.07089","article-title":"SmgGDS as a Crucial Mediator of the Inhibitory Effects of Statins on Cardiac Hypertrophy and Fibrosis: Novel Mechanism of the Pleiotropic Effects of Statins","volume":"67","author":"Kudo","year":"2016","journal-title":"Hypertension"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0002-9149(00)01004-3","article-title":"Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension","volume":"86","author":"Su","year":"2000","journal-title":"Am. J. Cardiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/cvr\/cvp135","article-title":"Rho kinase-1 mediates cardiac fibrosis by regulating fibroblast precursor cell differentiation","volume":"83","author":"Haudek","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1096\/fj.12-217018","article-title":"FHL2 prevents cardiac hypertrophy in mice with cardiac-specific deletion of ROCK2","volume":"27","author":"Okamoto","year":"2013","journal-title":"FASEB J."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"7348","DOI":"10.1096\/fj.201802510R","article-title":"Disruption of both ROCK1 and ROCK2 genes in cardiomyocytes promotes autophagy and reduces cardiac fibrosis during aging","volume":"33","author":"Shi","year":"2019","journal-title":"FASEB J."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/ajh\/hpt234","article-title":"Increased rho-kinase activity in hypertensive patients with left ventricular hypertrophy","volume":"27","author":"Gabrielli","year":"2014","journal-title":"Am. J. Hypertens."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Somers, T., Siddiqi, S., Morshuis, W.J., Russel, F.G.M., and Schirris, T.J.J. (2023). Statins and Cardiomyocyte Metabolism, Friend or Foe?. J. Cardiovasc. Dev. Dis., 10.","DOI":"10.3390\/jcdd10100417"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3892\/etm.2021.9655","article-title":"Inhibition of the mevalonate pathway improves myocardial fibrosis","volume":"21","author":"Xu","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijcard.2018.06.061","article-title":"Simvastatin reduces TGF-\u03b21-induced SMAD2\/3-dependent human ventricular fibroblasts differentiation: Role of protein phosphatase activation","volume":"270","author":"Rizvi","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/ehf2.12509","article-title":"Impact of statins on cellular respiration and de-differentiation of myofibroblasts in human failing hearts","volume":"6","author":"Emelyanova","year":"2019","journal-title":"ESC Heart. Fail."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Kuo, H.F., Hsieh, C.C., Wang, S.C., Chang, C.Y., Hung, C.H., Kuo, P.L., Liu, Y.R., Li, C.Y., and Liu, P.L. (2019). Simvastatin Attenuates Cardiac Fibrosis via Regulation of Cardiomyocyte-Derived Exosome Secretion. J. Clin. Med., 8.","DOI":"10.3390\/jcm8060794"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1440-1681.2005.04256.x","article-title":"In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: Implications for ventricular remodelling","volume":"32","author":"Martin","year":"2005","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/01.fjc.0000211791.22411.0d","article-title":"Pitavastatin improves cardiac function and survival in association with suppression of the myocardial endothelin system in a rat model of hypertensive heart failure","volume":"47","author":"Saka","year":"2006","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1210\/en.2006-1355","article-title":"Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats","volume":"148","author":"Habibi","year":"2007","journal-title":"Endocrinology"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000534933","article-title":"Simvastatin Attenuates Cardiac Fibrosis under Pathophysiological Conditions of Heart Failure with Preserved Left Ventricular Ejection Fraction by Inhibiting TGF-\u03b2 Signaling","volume":"109","author":"Marunouchi","year":"2024","journal-title":"Pharmacology"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.7150\/thno.48153","article-title":"Endothelial Klf2-Foxp1-TGF\u03b2 signal mediates the inhibitory effects of simvastatin on maladaptive cardiac remodeling","volume":"11","author":"Li","year":"2021","journal-title":"Theranostics"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1111\/jcmm.13891","article-title":"Cardioprotective cytokine interleukin-33 is up-regulated by statins in human cardiac tissue","volume":"22","author":"Pentz","year":"2018","journal-title":"J. Cell Mol. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.atherosclerosis.2011.02.036","article-title":"Simvastatin preserves diastolic function in experimental hypercholesterolemia independently of its lipid lowering effect","volume":"216","author":"Mannheim","year":"2011","journal-title":"Atherosclerosis"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.biopha.2016.06.034","article-title":"Amlodipine and atorvastatin improve ventricular hypertrophy and diastolic function via inhibiting TNF-alpha, IL-1beta and NF-kappaB inflammatory cytokine networks in elderly spontaneously hypertensive rats","volume":"83","author":"Lu","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ijcard.2017.04.103","article-title":"Atorvastatin reduces cardiac and adipose tissue inflammation in rats with metabolic syndrome","volume":"240","author":"Yamada","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2169\/internalmedicine.46.0021","article-title":"Impact of statin therapy on systemic inflammation, left ventricular systolic and diastolic function and prognosis in low risk ischemic heart disease patients without history of congestive heart failure","volume":"46","author":"Okura","year":"2007","journal-title":"Intern. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.amjcard.2011.01.054","article-title":"Effect of low-dose (1 mg\/day) pitavastatin on left ventricular diastolic function and albuminuria in patients with hyperlipidemia","volume":"107","author":"Yagi","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Ovchinnikov, A., Belyavskiy, E., Potekhina, A., and Ageev, F. (2022). Asymptomatic Left Ventricular Hypertrophy Is a Potent Risk Factor for the Development of HFpEF but Not HFrEF: Results of a Retrospective Cohort Study. J. Clin. Med., 11.","DOI":"10.3390\/jcm11133885"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jacl.2017.02.016","article-title":"Effects of atorvastatin treatment on left ventricular diastolic function in peritoneal dialysis patients - The ALEVENT clinical trial","volume":"11","author":"Wu","year":"2017","journal-title":"J. Clin. Lipidol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41569-022-00679-9","article-title":"Epicardial adipose tissue in contemporary cardiology","volume":"19","author":"Iacobellis","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e009975","DOI":"10.1161\/JAHA.118.009975","article-title":"Association of Volumetric Epicardial Adipose Tissue Quantification and Cardiac Structure and Function","volume":"7","author":"Nerlekar","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"e009238","DOI":"10.1161\/CIRCHEARTFAILURE.121.009238","article-title":"Epicardial Adipose Tissue and Outcome in Heart Failure With Mid-Range and Preserved Ejection Fraction","volume":"15","author":"Manintveld","year":"2022","journal-title":"Circ. Heart Fail."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ijcard.2018.06.106","article-title":"Statin therapy modulates thickness and inflammatory profile of human epicardial adipose tissue","volume":"274","author":"Parisi","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4250\/jcu.2010.18.4.121","article-title":"Effects of statins on the epicardial fat thickness in patients with coronary artery stenosis underwent percutaneous coronary intervention: Comparison of atorvastatin with simvastatin\/ezetimibe","volume":"18","author":"Park","year":"2010","journal-title":"J. Cardiovasc. Ultrasound."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.amjcard.2015.07.067","article-title":"Effects of Atorvastatin (80 mg) Therapy on Quantity of Epicardial Adipose Tissue in Patients Undergoing Pulmonary Vein Isolation for Atrial Fibrillation","volume":"116","author":"Soucek","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.jacc.2012.12.051","article-title":"Effect of intensive versus moderate lipid-lowering therapy on epicardial adipose tissue in hyperlipidemic post-menopausal women: A substudy of the BELLES trial (Beyond Endorsed Lipid Lowering with EBT Scanning)","volume":"61","author":"Alexopoulos","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_144","first-page":"303","article-title":"Statins in heart failure: Do we need another trial?","volume":"9","author":"Bonsu","year":"2013","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.mayocp.2012.02.018","article-title":"Statins in heart failure: The paradox between large randomized clinical trials and real life","volume":"87","author":"Gastelurrutia","year":"2012","journal-title":"Mayo Clin. Proc."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00228-012-1400-9","article-title":"Relationship between recommended chronic heart failure treatments and mortality over 8 years in real-world conditions: A pharmacoepidemiological study","volume":"69","author":"Maison","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"687585","DOI":"10.3389\/fcvm.2021.687585","article-title":"Hydrophilic or Lipophilic Statins?","volume":"8","author":"Climent","year":"2021","journal-title":"Front Cardiovasc Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1161\/CIRCHEARTFAILURE.114.001730","article-title":"Association between use of statins and outcomes in heart failure with reduced ejection fraction: Prospective propensity score matched cohort study of 21 864 patients in the Swedish Heart Failure Registry","volume":"8","author":"Alehagen","year":"2015","journal-title":"Circ. Heart Fail."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12944-019-1135-z","article-title":"Association of statin use and clinical outcomes in heart failure patients: A systematic review and meta-analysis","volume":"18","author":"Anker","year":"2019","journal-title":"Lipids Health Dis."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1253\/circj.CJ-15-0016","article-title":"Statins beneficial for heart failure with preserved ejection fraction but not heart failure with reduced ejection fraction?","volume":"79","author":"Ohte","year":"2015","journal-title":"Circ. J."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1161\/CIRCULATIONAHA.113.001475","article-title":"Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: A community-based study","volume":"128","author":"Zakeri","year":"2013","journal-title":"Circulation"},{"key":"ref_155","first-page":"418","article-title":"Statins improves functional capacity and restores LV diastolic reserve in patients with heart failure with preserved left ventricular ejection fraction","volume":"21","author":"Ovchinnikov","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1001\/jamacardio.2018.0128","article-title":"Association between hemodynamic markers of pulmonary hypertension and outcomes in heart failure with preserved ejection fraction","volume":"3","author":"Vanderpool","year":"2018","journal-title":"JAMA Cardiol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00380-017-0957-8","article-title":"Statin therapy improves survival in patients with severe pulmonary hypertension: A propensity score matching study","volume":"32","author":"Holzhauser","year":"2017","journal-title":"Heart Vessels."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/CIRCULATIONAHA.104.519876","article-title":"Statin therapy may be associated with lower mortality in patients with diastolic heart failure: A preliminary report","volume":"112","author":"Fukuta","year":"2005","journal-title":"Circulation."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2143\/AC.63.6.2033384","article-title":"Statin therapy and mortality among patients hospitalized with heart failure and preserved left ventricular function--a preliminary report","volume":"63","author":"Roik","year":"2008","journal-title":"Acta Cardiol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.amjcard.2007.08.050","article-title":"Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients >or=65 years of age with heart failure and preserved left ventricular systolic function","volume":"101","author":"Shah","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/clc.20615","article-title":"Statin therapy in patients with diastolic heart failure","volume":"33","author":"Tehrani","year":"2010","journal-title":"Clin. Cardiol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ijcard.2008.11.042","article-title":"Mortality and morbidity of newly diagnosed heart failure treated with statins: A propensity-adjusted cohort study","volume":"140","author":"Romero","year":"2010","journal-title":"Int. J. Cardiol."},{"key":"ref_163","first-page":"602","article-title":"Prognostic factors and long-term survival after initial diagnosis of heart failure","volume":"138","year":"2012","journal-title":"Med. Clin. (Barc.)"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jjcc.2013.03.013","article-title":"Clinical characteristics and long-term clinical outcomes of Japanese heart failure patients with preserved versus reduced left ventricular ejection fraction: A prospective cohort of Shinken Database 2004\u20132011","volume":"62","author":"Kaneko","year":"2013","journal-title":"J. Cardiol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1253\/circj.CJ-14-0865","article-title":"Prognostic impact of statin use in patients with heart failure and preserved ejection fraction","volume":"79","author":"Nochioka","year":"2015","journal-title":"Circ. J."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1161\/CIRCHEARTFAILURE.115.002143","article-title":"Association Between Use of Statins and Mortality in Patients With Heart Failure and Ejection Fraction of \u226550","volume":"8","author":"Alehagen","year":"2015","journal-title":"Circ. Heart Fail."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ijcard.2015.01.063","article-title":"Predictors of two-year mortality in Asian patients with heart failure and preserved ejection fraction","volume":"183","author":"Yap","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijcard.2017.12.109","article-title":"Favorable effects of statins in the treatment of heart failure with preserved ejection fraction in patients without ischemic heart disease","volume":"255","author":"Tsujimoto","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1253\/circj.CJ-18-0639","article-title":"Effect of Statins on Mortality in Heart Failure With Preserved Ejection Fraction Without Coronary Artery Disease- Report From the JASPER Study","volume":"83","author":"Marume","year":"2019","journal-title":"Circ. J."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.amjcard.2013.12.023","article-title":"Meta-analysis of the effect of statins on mortality in patients with preserved ejection fraction","volume":"113","author":"Liu","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ijcard.2016.03.186","article-title":"The effect of statins on mortality in heart failure with preserved ejection fraction: A meta-analysis of propensity score analyses","volume":"214","author":"Fukuta","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00392-019-01430-0","article-title":"Non-cardiac comorbidities and mortality in patients with heart failure with reduced vs. preserved ejection fraction: A study using the Swedish Heart Failure Registry","volume":"108","author":"Ergatoudes","year":"2019","journal-title":"Clin. Res. Cardiol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1161\/CIRCULATIONAHA.120.045810","article-title":"Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure With Preserved Ejection Fraction: Results From the PROMIS-HFpEF Study","volume":"142","author":"Tromp","year":"2020","journal-title":"Circulation"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"98","DOI":"10.7326\/0003-4819-138-2-200301210-00010","article-title":"Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency","volume":"138","author":"Tonelli","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.chest.2017.02.002","article-title":"The Impact of Statin Drug Use on All-Cause Mortality in Patients With COPD: A Population-Based Cohort Study","volume":"152","author":"Raymakers","year":"2017","journal-title":"Chest"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1472-8206.2004.00299.x","article-title":"Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update","volume":"19","author":"Schachter","year":"2005","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1124\/dmd.30.11.1158","article-title":"Liver-specific distribution of rosuvastatin in rats: Comparison with pravastatin and simvastatin","volume":"30","author":"Nezasa","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.atherosclerosis.2015.05.022","article-title":"Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials","volume":"241","author":"Sahebkar","year":"2015","journal-title":"Atherosclerosis"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.amjcard.2009.07.055","article-title":"Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure","volume":"104","author":"Lipinski","year":"2009","journal-title":"Am. J. Cardiol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1248\/bpb.b15-00126","article-title":"Effects of Statins on Left Ventricular Diastolic Function in Patients with Dyslipidemia and Diastolic Dysfunction (Stat-LVDF Study)","volume":"38","author":"Morimoto","year":"2015","journal-title":"Biol. Pharm. Bull."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jacl.2011.08.006","article-title":"The differential effect of statins on oxidative stress and endothelial function: Atorvastatin versus pravastatin","volume":"6","author":"Murrow","year":"2012","journal-title":"J. Clin. Lipidol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"174906","DOI":"10.1016\/j.ejphar.2022.174906","article-title":"Molecular targets of statins and their potential side effects: Not all the glitter is gold","volume":"922","author":"Patel","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.jacc.2016.02.071","article-title":"Statin-Associated Side Effects","volume":"67","author":"Thompson","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"e009835","DOI":"10.1161\/JAHA.118.009835","article-title":"Effects of Coenzyme Q10 on Statin-Induced Myopathy: An Updated Meta-Analysis of Randomized Controlled Trials","volume":"7","author":"Qu","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Turner, R.M., and Pirmohamed, M. (2019). Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components. J. Clin. Med., 9.","DOI":"10.3390\/jcm9010022"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1093\/eurheartj\/ehy182","article-title":"Adverse effects of statin therapy: Perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract","volume":"39","author":"ach","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2174\/157339913804143225","article-title":"Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes","volume":"9","author":"Fu","year":"2013","journal-title":"Curr. Diabetes Rev."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"6211","DOI":"10.2147\/DDDT.S87979","article-title":"Different effects of statins on induction of diabetes mellitus: An experimental study","volume":"9","author":"Zhao","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/MOL.0000000000000172","article-title":"Statins and diabetes risk: How real is it and what are the mechanisms?","volume":"26","author":"Robinson","year":"2015","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/mus.27447","article-title":"Statins and the risk of polyneuropathy: A systematic review and two meta-analyses","volume":"65","author":"Wannarong","year":"2022","journal-title":"Muscle Nerve."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/ehjcvp\/pvz079","article-title":"An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome","volume":"6","author":"Drexel","year":"2020","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/ejhf.2064","article-title":"Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial","volume":"22","author":"Anker","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"e010401","DOI":"10.1136\/bmjopen-2015-010401","article-title":"Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: A systematic review","volume":"6","author":"Ravnskov","year":"2016","journal-title":"BMJ Open"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/ije\/dyv031","article-title":"LDL cholesterol still a problem in old age? A Mendelian randomization study","volume":"44","author":"Postmus","year":"2015","journal-title":"Int. J. Epidemiol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11883-019-0793-7","article-title":"Role of Statin Therapy in Primary Prevention of Cardiovascular Disease in Elderly Patients","volume":"21","author":"Strandberg","year":"2019","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.amjcard.2013.08.047","article-title":"Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study)","volume":"113","author":"Arena","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"e005036","DOI":"10.1161\/CIRCHEARTFAILURE.118.005036","article-title":"IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction","volume":"11","author":"Trankle","year":"2018","journal-title":"Circ. Heart Fail."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/9\/4958\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:38:24Z","timestamp":1760107104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/9\/4958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,1]]},"references-count":200,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["ijms25094958"],"URL":"https:\/\/doi.org\/10.3390\/ijms25094958","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,1]]}}}